Efficacy and safety of the Shugan Jieyu capsule as a complementary treatment for functional dyspepsia: A systematic review and meta-analysis
Abstract
Background: To evaluate the efficacy and safety of the Shugan Jieyu capsule as a complementary treatment for functional dyspepsia (FD).
Methods: Seven electronic databases were searched for randomized controlled trials (RCTs) on Shugan Jieyu capsule treatment for FD with a scientifically rigorous search strategy. The quality of the literature was assessed using the Risk of Bias 2 tool, a meta-analysis was performed with RevMan v5.3 and Stata 12.0.
Results: Thirty-two RCTs containing 3582 participants were included in the meta-analysis. The combination of the Shugan Jieyu capsule with Western medications (WM) was more efficacious than treatment with WM alone (relative risk [RR] = 1.29, 95% confidence interval [CI]: [1.23, 1.35], P < .00001) and had comparable safety (RR = 1.0, 95% CI: [0.68, 1.47], P = .99). This combination also reduced the rate of disease recurrence (RR = 0.24, 95% CI: [0.14, 0.40], P < .00001) and patients' gastrointestinal symptom scores (standardized mean difference [SMD] = -1.59, 95% CI: [-2.00, -1.18], P < .00001).
Conclusion: While current evidence suggests SG as a complementary therapy may enhance FD treatment efficacy without increasing safety risks, these findings are constrained by the low methodological quality of included studies and exclusive derivation from Chinese populations. Definitive conclusions require future high-quality, multicenter RCTs with standardized outcome measures and diverse ethnic cohorts.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 3,582 participants or records.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.